Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXELDERM vs ABELCET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability, leading to leakage of intracellular ions and cell death. The lipid complex formulation (ABELCET) alters pharmacokinetics to reduce nephrotoxicity while retaining antifungal activity.
Tinea pedis,Tinea cruris,Tinea corporis,Tinea versicolor
Invasive fungal infections refractory to amphotericin B deoxycholate or in patients intolerant to that formulation,Aspergillosis,Candidiasis,Cryptococcosis,Blastomycosis,Histoplasmosis,Coccidioidomycosis,Zygomycosis,Fungal sinusitis,Empiric therapy in febrile neutropenic patients (off-label),Visceral leishmaniasis (off-label)
Apply a thin layer to affected skin twice daily (morning and evening).
5 mg/kg IV once daily infused over 2-2.5 hours. For aspergillosis, duration is typically 2-4 weeks total.
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Terminal elimination half-life is approximately 120–180 hours (mean ~153 h) in adults with normal renal and hepatic function. This long half-life reflects slow redistribution from tissues and supports once-daily dosing after a loading regimen.
Minimal systemic absorption; when absorbed, primarily metabolized in the liver via oxidation and glucuronidation.
Amphotericin B is not significantly metabolized in humans; it is eliminated primarily via biliary excretion with negligible renal metabolism.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
Renal excretion is minimal (<1% unchanged drug); the primary route of elimination is via the hepatobiliary system, with the majority of the dose recovered in feces as unchanged drug and metabolites. Biliary/fecal elimination accounts for >90% of clearance.
Not applicable; systemic levels are undetectable with topical use.
More than 99% bound to plasma proteins, primarily to albumin and lipoproteins (e.g., LDL and HDL).
Not applicable; negligible systemic absorption.
Volume of distribution is approximately 0.5–1.0 L/kg, indicating extensive tissue distribution (e.g., liver, spleen, lung, kidney) with limited penetration into cerebrospinal fluid and vitreous humor.
Topical: negligible systemic bioavailability (<1%) due to poor percutaneous absorption.
Not applicable; only administered intravenously. Oral bioavailability is negligible (less than 5%) due to poor gastrointestinal absorption and degradation in the GI tract.
No dosage adjustment required for renal impairment.
No dosage adjustment required, but renal function should be monitored; consider dose adjustment if Cr Cl < 30 m L/min or if significant nephrotoxicity occurs (e.g., doubling of serum creatinine).
No dosage adjustment required for hepatic impairment.
No specific adjustment; use with caution in severe hepatic impairment.
Safety and efficacy in pediatric patients below 12 years have not been established; see prescribing information for age-specific recommendations.
Same dosing as adults (5 mg/kg/day IV); safety and efficacy established.
No specific geriatric dose adjustments; use caution due to higher risk of adverse effects from prolonged use.
No specific adjustment, but monitor renal function and electrolyte balance due to higher risk of toxicity.
None.
WARNING: Should be used primarily for treatment of progressive, potentially life-threatening fungal infections in patients intolerant to conventional amphotericin B deoxycholate or whose infection is refractory to that formulation. Not interchangeable with other amphotericin B products. Verify correct product prior to administration. Administer by intravenous infusion only.
Avoid contact with eyes, nose, mouth, or other mucous membranes. Discontinue if irritation or sensitization occurs. Not for oral or ophthalmic use. Use in children under 12 years not established.
Nephrotoxicity: monitor renal function closely; may cause azotemia, hypokalemia, hypomagnesemia,Hypersensitivity reactions: anaphylaxis, bronchospasm, flushing, hypotension,Infusion-related reactions: fever, chills, rigors, headache, nausea, vomiting,Cardiotoxicity: arrhythmias, cardiac arrest (especially during rapid infusion),Hepatotoxicity: elevated liver enzymes, bilirubin,Hematologic toxicity: anemia, thrombocytopenia, leukopenia,Electrolyte disturbances: hypokalemia, hypomagnesemia, hyponatremia,Pulmonary toxicity: dyspnea, respiratory failure (rare),Prior to infusion: premedicate with antipyretics, antihistamines, and corticosteroids to reduce infusion reactions
Known hypersensitivity to sulconazole or any component of the formulation.
Hypersensitivity to amphotericin B or any component of the formulation,Concurrent administration with other nephrotoxic drugs (e.g., cyclosporine, tacrolimus, aminoglycosides) unless benefit outweighs risk,Severe pre-existing renal impairment (relative contraindication; use only if no alternative)
None known.
No known food interactions. Maintain adequate hydration.
Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.
Pregnancy Category B. Animal studies with amphotericin B deoxycholate have shown no evidence of fetal harm. There are no adequate and well-controlled studies in pregnant women. However, systemic fungal infections pose significant maternal and fetal risk if untreated. Use only if clearly needed.
Not known if excreted in breast milk. Caution in nursing mothers; limited data. M/P ratio not available.
It is not known whether amphotericin B is excreted in human milk. Because many drugs are excreted in human milk and due to the potential for adverse effects in nursing infants, the decision to discontinue nursing or discontinue the drug should be made, taking into account the importance of the drug to the mother. M/P ratio unknown.
No dose adjustment required for topical use; insufficient data for systemic absorption changes.
No specific dosing adjustments are recommended for pregnancy. However, given the potential for renal impairment and electrolyte disturbances, close monitoring is warranted. Dose adjustments are primarily based on renal function, which may be altered in pregnancy.
Apply sparingly to affected area; avoid use on mucous membranes or intertriginous areas. Discontinue if irritation occurs. Not recommended for use under occlusive dressings.
Monitor renal function and electrolytes closely; premedicate with diphenhydramine and acetaminophen to reduce infusion-related reactions; do not mix with saline or other electrolytes; administer via in-line filter (5 micron) only; ensure adequate hydration to prevent nephrotoxicity.
Use only on the skin as directed; avoid contact with eyes, mouth, or open wounds.,Wash hands before and after applying unless treating hands.,Do not cover the treated area with bandages or wrappings unless directed by a doctor.,Stop use and consult doctor if condition worsens or does not improve within 2 weeks.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
This medication is given intravenously and may cause fever, chills, or rigors during infusion.,Report any breathing difficulty, chest pain, or severe reaction immediately.,You may receive pre-medications to reduce side effects.,Stay well hydrated unless instructed otherwise.,Blood tests will be required to monitor kidney function and electrolytes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXELDERM vs ABELCET, answered by our medical review team.
EXELDERM is a Topical Antifungal that works by Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.. ABELCET is a Polyene antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability, leading to leakage of intracellular ions and cell death. The lipid complex formulation (ABELCET) alters pharmacokinetics to reduce nephrotoxicity while retaining antifungal activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXELDERM and ABELCET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXELDERM is: Apply a thin layer to affected skin twice daily (morning and evening).. The standard adult dose of ABELCET is: 5 mg/kg IV once daily infused over 2-2.5 hours. For aspergillosis, duration is typically 2-4 weeks total.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXELDERM and ABELCET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXELDERM is classified as Category C. Category B: No teratogenic effects in animal studies; no adequate human studies in first trimester. Avoid use in first trimester unless clearly needed.. ABELCET is classified as Category C. Pregnancy Category B. Animal studies with amphotericin B deoxycholate have shown no evidence of fetal harm. There are no adequate and well-controlled studies in pregnant women. How. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.